INR 53.16
(-0.91%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 14.21 Million INR | -4.61% |
2022 | 89.62 Million INR | -11.14% |
2021 | 100.86 Million INR | 58.26% |
2020 | 63.73 Million INR | -15.61% |
2019 | 75.52 Million INR | 10.53% |
2018 | 68.32 Million INR | 71.4% |
2017 | 39.86 Million INR | -56.32% |
2016 | 91.26 Million INR | 285.96% |
2015 | 23.64 Million INR | -12.64% |
2014 | 27.07 Million INR | 7.82% |
2013 | 25.1 Million INR | 34.98% |
2012 | 18.6 Million INR | 6.17% |
2011 | 17.51 Million INR | 54.2% |
2010 | 11.36 Million INR | 250.65% |
2009 | 3.24 Million INR | -79.65% |
2008 | 15.92 Million INR | 40.04% |
2007 | 11.36 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 20.01 Million INR | -86.52% |
2023 FY | 85.49 Million INR | -4.61% |
2023 Q1 | 20.26 Million INR | -26.64% |
2023 Q3 | 9.05 Million INR | -26.0% |
2023 Q2 | 12.23 Million INR | -39.66% |
2023 Q4 | 54.42 Million INR | 501.39% |
2022 FY | 89.62 Million INR | -11.14% |
2022 Q4 | 27.62 Million INR | -3.77% |
2022 Q1 | 16.07 Million INR | -47.81% |
2022 Q2 | 17.21 Million INR | 7.13% |
2022 Q3 | 28.71 Million INR | 66.75% |
2021 Q2 | 24.06 Million INR | 15.33% |
2021 Q1 | 20.86 Million INR | 255.18% |
2021 Q3 | 25.14 Million INR | 4.48% |
2021 Q4 | 30.79 Million INR | 22.46% |
2021 FY | 100.86 Million INR | 58.26% |
2020 FY | 63.73 Million INR | -15.61% |
2020 Q1 | 13.31 Million INR | -9.14% |
2020 Q4 | 5.87 Million INR | -79.31% |
2020 Q3 | 28.39 Million INR | 114.31% |
2020 Q2 | 13.24 Million INR | -0.47% |
2019 Q3 | 27.64 Million INR | 68.72% |
2019 Q4 | 14.65 Million INR | -47.0% |
2019 Q1 | 16.84 Million INR | -43.59% |
2019 FY | 75.52 Million INR | 10.53% |
2019 Q2 | 16.38 Million INR | -2.71% |
2018 Q2 | 15.87 Million INR | 60.0% |
2018 Q1 | 9.92 Million INR | -55.75% |
2018 Q3 | 12.67 Million INR | -20.15% |
2018 FY | 68.32 Million INR | 71.4% |
2018 Q4 | 29.85 Million INR | 135.54% |
2017 FY | 39.86 Million INR | -56.32% |
2017 Q4 | 22.42 Million INR | 342.23% |
2017 Q3 | 5.07 Million INR | -13.97% |
2017 Q2 | 5.89 Million INR | 134.31% |
2017 Q1 | 2.51 Million INR | -71.63% |
2016 Q2 | 12.82 Million INR | 360.45% |
2016 Q3 | 9.2 Million INR | -28.22% |
2016 FY | 91.26 Million INR | 285.96% |
2016 Q4 | 8.86 Million INR | -3.71% |
2016 Q1 | 2.78 Million INR | -44.56% |
2015 Q4 | 5.02 Million INR | -35.06% |
2015 FY | 23.64 Million INR | -12.64% |
2015 Q3 | 7.73 Million INR | 413.66% |
2015 Q2 | -2.46 Million INR | -177.19% |
2015 Q1 | 3.19 Million INR | -51.79% |
2014 Q4 | 6.62 Million INR | 34.47% |
2014 FY | 27.07 Million INR | 7.82% |
2014 Q1 | 5.75 Million INR | 750.17% |
2014 Q2 | 9.76 Million INR | 69.76% |
2014 Q3 | 4.93 Million INR | -49.49% |
2013 Q4 | -884.39 Thousand INR | -109.63% |
2013 FY | 25.1 Million INR | 34.98% |
2013 Q1 | 2.5 Million INR | 613.14% |
2013 Q2 | 14.3 Million INR | 471.66% |
2013 Q3 | 9.18 Million INR | -35.77% |
2012 Q3 | 11.75 Million INR | 95.43% |
2012 Q1 | 4.74 Million INR | -10.23% |
2012 FY | 18.6 Million INR | 6.17% |
2012 Q2 | 6.01 Million INR | 26.77% |
2012 Q4 | -487.58 Thousand INR | -104.15% |
2011 Q3 | 4.55 Million INR | 0.0% |
2011 Q4 | 5.28 Million INR | 15.97% |
2011 FY | 17.51 Million INR | 54.2% |
2010 FY | 11.36 Million INR | 250.65% |
2009 FY | 3.24 Million INR | -79.65% |
2008 Q4 | 3.03 Million INR | 0.0% |
2008 FY | 15.92 Million INR | 40.04% |
2007 FY | 11.36 Million INR | 0.0% |
2007 Q4 | 1.87 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sigachi Industries Limited | 579.88 Million INR | 97.549% |
Ind-Swift Limited | 946.56 Million INR | 98.498% |
Innova Captab Limited | 931.03 Million INR | 98.473% |
Aarti Drugs Limited | 1.16 Billion INR | 98.783% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 99.538% |
Bajaj HealthCare Limited | 985.34 Million INR | 98.558% |
Sakar Healthcare Limited | 204.07 Million INR | 93.036% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.974% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 99.444% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 99.425% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | 91.239% |
Morepen Laboratories Limited | 1.98 Billion INR | 99.285% |
Sequent Scientific Limited | 2.9 Billion INR | 99.51% |
Wanbury Limited | 978.96 Million INR | 98.548% |
Laurus Labs Limited | 11.9 Billion INR | 99.881% |
Nectar Lifesciences Limited | 932.7 Million INR | 98.476% |
Gufic Biosciences Limited | 1.18 Billion INR | 98.802% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.878% |
Alembic Limited | 872.45 Million INR | 98.371% |
Hikal Limited | 4.46 Billion INR | 99.682% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.91% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.97% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 99.354% |
Themis Medicare Limited | 1.12 Billion INR | 98.738% |
RPG Life Sciences Limited | 1.63 Billion INR | 99.131% |
Lupin Limited | 125.09 Billion INR | 99.989% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 99.321% |
Wockhardt Limited | 8.48 Billion INR | 99.832% |
Vaishali Pharma Limited | 84.02 Million INR | 83.086% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 96.759% |
NATCO Pharma Limited | 10.05 Billion INR | 99.859% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.902% |
FDC Limited | 3.49 Billion INR | 99.594% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.9% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 96.554% |
Eris Lifesciences Limited | 4.94 Billion INR | 99.712% |
Windlas Biotech Limited | 1 Billion INR | 98.588% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.991% |
Mankind Pharma Limited | 29.27 Billion INR | 99.951% |
Venus Remedies Limited | 1.91 Billion INR | 99.258% |
ZIM Laboratories Limited | 1.01 Billion INR | 98.597% |
Neuland Laboratories Limited | 2.92 Billion INR | 99.515% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.904% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 98.677% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.989% |
Bal Pharma Limited | 555.62 Million INR | 97.442% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.985% |
Par Drugs and Chemicals Limited | 58.28 Million INR | 75.616% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 99.346% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 98.999% |
Shilpa Medicare Limited | 3.33 Billion INR | 99.574% |
Orchid Pharma Limited | 800.77 Million INR | 98.225% |
Albert David Limited | 1.02 Billion INR | 98.615% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.953% |
Hester Biosciences Limited | 908.84 Million INR | 98.436% |
Valiant Laboratories Limited | 138.02 Million INR | 89.703% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 98.987% |
Procter & Gamble Health Limited | 2.99 Billion INR | 99.526% |
Granules India Limited | 10.31 Billion INR | 99.862% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.957% |
Medicamen Biotech Limited | 335.16 Million INR | 95.759% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.789% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 96.88% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -108.402% |
Medico Remedies Limited | 59.67 Million INR | 76.183% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.925% |
Syncom Formulations (India) Limited | 345.63 Million INR | 95.888% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 99.331% |
Brooks Laboratories Limited | 51.18 Million INR | 72.229% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.978% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.934% |
Suven Life Sciences Limited | 109.75 Million INR | 87.05% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | 69.207% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.845% |
Indoco Remedies Limited | 12.06 Billion INR | 99.882% |
Alpa Laboratories Limited | 127.38 Million INR | 88.842% |
Lasa Supergenerics Limited | 291.17 Million INR | 95.119% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 99.538% |